Evidence-based guideline for the safe handling, preparation, administration, and disposal of hazardous drugs in healthcare settings, including engineering controls, PPE, and exposure management.
A comprehensive, evidence-based clinical guideline for the safe handling, preparation, administration, and disposal of hazardous drugs in all healthcare settings. This document synthesizes recommendations from multiple authoritative professional societies, federal regulatory agencies, and expert consensus groups in pharmacy, oncology, occupational safety, and healthcare quality to provide a single, integrated reference for all personnel who may encounter hazardous drugs in clinical practice.
Hazardous drugs — defined as pharmaceutical agents that exhibit one or more of six characteristics including carcinogenicity, teratogenicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, or structural/toxicity similarity to existing hazardous drugs — pose well-documented occupational risks to healthcare workers involved in their manufacture, transport, preparation, administration, and disposal. Decades of surface contamination studies have demonstrated that hazardous drug residues are present throughout healthcare facilities, including pharmacies, nursing stations, patient rooms, and even non-clinical areas, despite adherence to safe handling protocols.1 Epidemiological studies have associated occupational exposure with adverse reproductive outcomes, including increased rates of spontaneous abortion, congenital malformations, and infertility, as well as acute symptoms such as hair loss, skin rashes, and chromosomal damage.2
The regulatory and professional practice landscape for hazardous drug handling has evolved substantially over the past four decades. Current standards of practice mandate a comprehensive, multi-layered approach that integrates hazard identification, risk assessment, engineering controls, administrative controls, personal protective equipment, medical surveillance, training, and continuous quality monitoring. The enforceable compounding standards that took effect July 2018 represent the first legally binding requirements for hazardous drug handling in many jurisdictions, supplementing existing occupational safety regulations and voluntary professional guidelines.3
This guideline is intended for pharmacists, pharmacy technicians, nurses, physicians, environmental services personnel, safety officers, and administrators responsible for any aspect of the hazardous drug lifecycle — from receipt at the loading dock through final waste disposal. Recommendations address both antineoplastic and non-antineoplastic hazardous drugs, with explicit guidance on risk-stratified approaches that calibrate the intensity of protective measures to the nature and frequency of exposure.
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Drug Identification, Risk Assessment, and Engineering Controls | Hazardous drug definitions and criteria; national hazardous drug list organization (Table 1, Table 2, Table 3); exposure routes and health effects; facility-level risk assessment; biological safety cabinets; compounding aseptic containment isolators; closed-system drug transfer devices; ventilation requirements; negative pressure rooms; containment segregated compounding areas |
| Part 2 | Personal Protective Equipment and Safe Handling Procedures | Complete PPE specifications by activity; chemotherapy-tested gloves; protective gowns; eye and face protection; respiratory protection; procedures for receiving, unpacking, and storage; compounding and preparation; administration by route; patient care and body fluid handling; transport within and between facilities |
| Part 3 | Spill Management, Waste Disposal, and Decontamination | Spill classification and response procedures; spill kit contents and use; small spill vs. large spill protocols; personnel exposure during spills; hazardous drug waste segregation; trace contamination waste; bulk waste; disposal regulations; surface decontamination and cleaning procedures; deactivation, decontamination, and cleaning agents |
| Part 4 | Medical Surveillance, Training, Reproductive Health, and Special Topics | Medical surveillance program design; baseline and periodic health assessments; biological monitoring; reproductive health counseling and alternative duty policies; training and competency requirements; documentation and record-keeping; non-antineoplastic hazardous drug considerations; home administration guidance; quality assurance and continuous improvement |
Scope and Applicability: This guideline applies to all healthcare personnel who may be exposed to hazardous drugs through any phase of the drug lifecycle, including but not limited to: pharmacists, pharmacy technicians, nurses, physicians, veterinary staff, environmental services workers, shipping and receiving personnel, and maintenance workers. It covers all care settings including acute care hospitals, outpatient infusion centers, physician offices, home care, long-term care facilities, and veterinary practices.
Limitations: No guideline can anticipate all institutional configurations, patient populations, or drug formulations. This document is not intended to replace required compliance with applicable federal, state, and local regulations. Facilities must conduct individualized assessments of their hazardous drug handling activities and develop site-specific policies accordingly. The drug classification tables referenced herein are subject to periodic revision; facilities should monitor for updated national hazardous drug lists and adjust their policies accordingly.
Connor TH, DeBord DG, Pretty JR, et al. “Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers.” J Occup Environ Med. 52(10):1019-1027, 2010. doi:10.1097/JOM.0b013e3181f72b63 ↩︎
Dranitsaris G, Johnston M, Poirier S, et al. “Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature.” J Oncol Pharm Pract. 11(2):69-78, 2005. doi:10.1191/1078155205jp155oa ↩︎
United States Pharmacopeia. General Chapter <800> Hazardous Drugs — Handling in Healthcare Settings. USP Compounding Compendium. Rockville, MD: United States Pharmacopeial Convention; 2017. Became enforceable December 1, 2019 (delayed to various state-specific dates; majority enforceable by 2020). ↩︎
Medical surveillance program design and components, biological monitoring, reproductive health counseling and alternative duty policies, training and competency assessment requirements, documentation and record-keeping, non-antineoplastic hazardous drug considerations, home administration guidance, and quality assurance.
Spill classification and step-by-step response procedures, spill kit contents, personnel exposure management during spills, hazardous drug waste segregation and disposal, and surface decontamination protocols including deactivation, decontamination, and cleaning agents.
Complete PPE specifications for hazardous drug handling by activity type, including glove, gown, eye/face, and respiratory protection requirements; detailed procedures for receiving, storage, compounding, administration, patient care, and transport.
Hazardous drug definitions, NIOSH classification criteria, national drug list organization, exposure routes and health effects, facility risk assessment, and complete engineering control specifications including BSCs, CACIs, CSTDs, and ventilation requirements.